RT Journal Article
SR Electronic
T1 Artificial intelligence to predict the risk of mortality from Covid-19: Insights from a Canadian Application
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20201632
DO 10.1101/2020.09.29.20201632
A1 Brett Snider
A1 Paige Phillips
A1 Aryn MacLean
A1 Edward McBean
A1 S. Andrew Gadsden
A1 John Yawney
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.29.20201632.abstract
AB The Severe Acute Respiratory Syndrome COVID-19 virus (SARS-CoV-2) has had enormous impacts, indicating need for non-pharmaceutical interventions (NPIs) using Artificial Intelligence (AI) modeling. Investigation of AI models and statistical models provides important insights within the province of Ontario as a case study application using patients’ physiological conditions, symptoms, and demographic information from datasets from Public Health Ontario (PHO) and the Public Health Agency of Canada (PHAC). The findings using XGBoost provide an accuracy of 0.9056 for PHO, and 0.935 for the PHAC datasets. Age is demonstrated to be the most important variable with the next two variables being Hospitalization and Occupation. Further, AI models demonstrate identify the importance of improved medical practice which evolved over the six months in treating COVID-19 virus during the pandemic, and that age is absolutely now the key factor, with much lower importance of other variables that were important to mortality near the beginning of the pandemic.An XGBoost model is shown to be fairly accurate when the training dataset surpasses 1000 cases, indicating that AI has definite potential to be a useful tool in the fight against COVID-19 even when caseload numbers needed for effective utilization of AI model are not large.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch funding by both the Natural Sciences Engineering Research Council (NSERC) under their special program for analyses of COVID-19 (ALLRP 549866-20) and by the University of Guelph Research Leadership Chair program are gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB / ethic approval was requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe case data used in this manuscript are publicly available from Ontario Health and Statistics Canada websites https://data.ontario.ca/dataset/f4112442-bdc8-45d2-be3c-12efae72fb27/resource/455fd63b-603d-4608-8216-7d8647f43350/download/conposcovidloc.csv https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310078101